ストックスクリーナーアプリを入手
147.86
0.85%
-1.27
アフターアワーズ：
147.90
0.04
+0.03%
前日終値:
$149.13
開ける：
$148.82
24時間の取引高:
2.45M
Relative Volume:
1.50
時価総額：
$21.68B
収益：
$9.61B
当期純損益:
$1.53B
株価収益率:
14.15
EPS:
10.453
ネットキャッシュフロー:
$1.85B
1週間 パフォーマンス:
+0.09%
1か月 パフォーマンス:
+6.74%
6か月 パフォーマンス:
+23.04%
1年 パフォーマンス:
-19.41%
1日の値動き範囲:
$147.54
$149.91
1週間の範囲:
$147.54
$151.92
52週間の値動き範囲:
$110.03
$185.00
Biogen Inc Stock (BIIB) Company Profile
BIIB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
147.86 | 21.86B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
813.53 | 735.18B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
186.60 | 450.37B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
225.14 | 401.96B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
121.80 | 238.94B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
86.58 | 217.38B | 63.43B | 16.42B | 14.72B | 6.4861 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-25 | 開始されました | Jefferies | Buy |
| 2025-07-21 | 再開されました | Truist | Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-04-04 | ダウングレード | Argus | Buy → Hold |
| 2025-02-11 | 開始されました | Bernstein | Mkt Perform |
| 2025-01-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-11-18 | ダウングレード | Needham | Buy → Hold |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-14 | 繰り返されました | Needham | Buy |
| 2024-02-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-12-20 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-12-07 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-24 | 繰り返されました | UBS | Buy |
| 2023-05-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-04-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | アップグレード | Goldman | Neutral → Buy |
| 2022-10-13 | アップグレード | Stifel | Hold → Buy |
| 2022-10-07 | アップグレード | Argus | Hold → Buy |
| 2022-09-28 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-28 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-04 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-04 | 繰り返されました | Cowen | Outperform |
| 2022-02-04 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-04 | 繰り返されました | Needham | Buy |
| 2022-02-04 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-04 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 繰り返されました | Robert W. Baird | Neutral |
| 2022-02-04 | 繰り返されました | Wedbush | Neutral |
| 2022-02-04 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-02-04 | 繰り返されました | Wolfe Research | Peer Perform |
| 2022-01-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-01-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-06-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 繰り返されました | Truist | Buy |
| 2021-06-11 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | アップグレード | UBS | Neutral → Buy |
| 2021-06-08 | アップグレード | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 繰り返されました | Barclays | Equal Weight |
| 2021-06-08 | アップグレード | Citigroup | Sell → Neutral |
| 2021-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-08 | 繰り返されました | Jefferies | Buy |
| 2021-06-08 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-06-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 繰り返されました | Stifel | Buy |
| 2021-06-08 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-06-07 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-06-07 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-01-29 | アップグレード | Stifel | Hold → Buy |
| 2020-11-10 | アップグレード | DZ Bank | Hold → Buy |
| 2020-11-09 | ダウングレード | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-11-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-04 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-11-04 | アップグレード | Jefferies | Hold → Buy |
| 2020-11-04 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-07-27 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-04-23 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-27 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | ダウングレード | Robert W. Baird | Neutral → Underperform |
すべてを表示
Biogen Inc (BIIB) 最新ニュース
Analyzing Biogen Inc. with multi timeframe charts2025 Top Gainers & Daily Volume Surge Signals - newser.com
Biogen (BIIB): Reassessing Valuation After Recent Share Price Momentum - simplywall.st
United States Biotechnology Market 2025: Industry - openPR.com
Why Biogen Inc. (IDP) stock stays on top picksWeekly Investment Summary & Safe Capital Growth Tips - newser.com
PEGylated Proteins Market See Incredible Growth 2025-2032 | Biogen Inc, Pfizer Inc, and UCB S.A. - openPR.com
Is Biogen Inc. stock a safe buy before earnings2025 Geopolitical Influence & Detailed Earnings Play Alerts - newser.com
United States Biosimilars Market is expected to reach US$ 171.79 - openPR.com
Nisa Investment Advisors LLC Has $6.39 Million Stock Position in Biogen Inc. $BIIB - MarketBeat
Brighton Jones LLC Purchases New Stake in Biogen Inc. $BIIB - MarketBeat
Is Biogen Inc. stock a top momentum playJuly 2025 Chart Watch & Weekly Watchlist for Hot Stocks - newser.com
Biogen (BIIB) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
Biogen Seeks To Stand Out in Lupus With New Anti-CD40L Data - BioSpace
Will Biogen Inc. (IDP) stock benefit from commodity supercycleJuly 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com
Volatility clustering patterns for Biogen Inc.Earnings Risk Summary & Fast Entry High Yield Tips - newser.com
Will Biogen Inc. (IDP) stock benefit from sector leadershipJuly 2025 Selloffs & Safe Capital Growth Tips - newser.com
Sumitomo Mitsui Trust Group Inc. Decreases Stake in Biogen Inc. $BIIB - MarketBeat
Key metrics from Biogen Inc.’s quarterly dataPortfolio Risk Summary & Technical Pattern Alert System - newser.com
Biogen Inc.’s volatility index tracking explainedMarket Performance Report & Verified Short-Term Plans - newser.com
Historical volatility pattern of Biogen Inc. visualizedLong Setup & Weekly Top Gainers Alerts - newser.com
United States Inflammatory Bowel Disease Market is expected - openPR.com
Will Biogen Inc. stock gain from strong economyJuly 2025 Earnings & Fast Gaining Stock Reports - Fundação Cultural do Pará
Institutional scanner results for Biogen Inc.July 2025 Rallies & Technical Analysis for Trade Confirmation - newser.com
Is Biogen Inc. (IDP) stock a buy on weaknessJuly 2025 Sector Moves & Consistent Profit Trade Alerts - newser.com
How to escape a deep drawdown in Biogen Inc.Weekly Loss Report & Daily Chart Pattern Signal Reports - newser.com
Biogen’s Felzartamab Trial: A New Hope for Kidney Transplant Patients - TipRanks
Biogen’s PMN Study: A Potential Game-Changer for Kidney Disease Treatment? - TipRanks
Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment? - TipRanks
Biogen’s Litifilimab Study: A Promising Step for Lupus Treatment - TipRanks
Biogen’s New Study on Felzartamab: A Potential Game-Changer for Kidney Transplant Patients - TipRanks
Biogen’s Study on Diroximel Fumarate: A Closer Look at Pregnancy Outcomes - TipRanks
Biogen’s Felzartamab Study: A Potential Game-Changer for IgA Nephropathy - TipRanks
Biogen’s Litifilimab Study: A Potential Game-Changer in Lupus Treatment? - TipRanks
Biogen’s Nusinersen Study: Exploring Pregnancy Outcomes in SMA Patients - TipRanks
Biogen’s Innovative Approach in SMA Treatment: ThecaFlex DRx™ System Study Update - TipRanks
Biogen’s Innovative Approach to SMA Treatment: A Study Update - TipRanks
Biogen’s New Study on Omaveloxolone: A Potential Game-Changer for Friedreich’s Ataxia - TipRanks
Biogen’s BIIB142 Study: A New Chapter in Drug Safety Evaluation - TipRanks
Biogen and Denali’s New Study on LRRK2-Associated Parkinson’s Disease: What Investors Need to Know - TipRanks
Biogen’s Innovative Study on Litifilimab Delivery: Market Implications and Study Insights - TipRanks
Biogen, Inc. Experiences Valuation Adjustment Amidst Market Performance Challenges - Markets Mojo
Biogen’s Pregnancy Exposure Study: Implications for MS Treatment Market - TipRanks
Biogen’s Zuranolone Study: A Potential Game-Changer for Postpartum Depression Treatment - TipRanks
Biogen’s Omaveloxolone Study: Assessing Safety During Pregnancy and Lactation - TipRanks
Biogen’s New MS Study: A Potential Game-Changer for Investors? - TipRanks
Biogen’s Omaveloxolone Study: A Closer Look at Long-Term Safety for Friedreich’s Ataxia - TipRanks
Biogen Still Has Competitive Advantages in Neurology, but Its Moat Looks Narrow - Morningstar
Health Canada Grants Authorization for LEQEMBI® (lecanemab) for the Treatment of Early Alzheimer’s Disease - Cantech Letter
Health Canada Grants Authorization for LEQEMBI® (lecanemab) for the Treatment of Early Alzheimer's Disease - Newswire Canada
AustralianSuper Pty Ltd Has $92.86 Million Stake in Biogen Inc. $BIIB - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Cuts Stock Position in Biogen Inc. $BIIB - MarketBeat
Using portfolio simulators with Biogen Inc. includedMarket Performance Report & Free Safe Entry Trade Signal Reports - newser.com
Biogen Inc (BIIB) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
0.53%
大文字化:
|
ボリューム (24 時間):